Boston Scientific Cuts 2026 Guidance Again as Watchman, Electrophysiology Businesses Struggle

Boston Scientific (NYSE: BSX) announced a reduction in its 2026 financial guidance for the second consecutive quarter, driven by persistent headwinds in its electrophysiology and Watchman left atrial appendage closure (LAAC) businesses. The company now expects net sales growth of 5.5% to 6.5%, down from the 7% to 8.5% forecast provided in April. Adjusted earnings per share (EPS) guidance was also trimmed to a range of $3.28 to $3.32 from $3.34 to $3.41. In February, the company had projected sales growth of 10.5% to 11.5% and EPS of $3.43 to $3.49.

CEO Mike Mahoney acknowledged the challenges during an investor call on Wednesday, stating, “This update today is not the outcome we plan or what you have come to expect from us … However, market conditions have evolved quickly, and it’s been a challenge to forecast effectively.”

• Boston Scientific cut 2026 sales growth forecast to 5.5%–6.5% (was 7%–8.5%) and EPS to $3.28–$3.32.

• Watchman growth slowed to 4.3% in Q2 2026, with expectations of flat to low-single-digit full-year growth.

• Electrophysiology revenue grew just over 9% year over year in Q2, but minimal sequential growth.

• Pulsed field ablation (PFA) now accounts for 80%–85% of U.S. ablation procedures, limiting growth offset.

• Company announced a global restructuring with $700–$800 million in pre-tax charges and ~$500 million in run-rate savings.

How the Technology Works

Boston Scientific’s Watchman device is a left atrial appendage closure (LAAC) implant used to reduce stroke risk in patients with atrial fibrillation (AFib) who are unable to take long-term oral anticoagulation. It is deployed via a catheter through the femoral vein and permanently seals the left atrial appendage, where blood clots commonly form in AFib patients.

The company’s electrophysiology portfolio includes catheters and mapping systems for cardiac ablation, including pulsed field ablation (PFA) technology (the Farapulse system) that uses non-thermal electric fields to ablate cardiac tissue, minimizing damage to surrounding structures. PFA has rapidly become the dominant ablation modality for AFib in the United States.

What the Evidence Shows

For the second quarter of 2026, Boston Scientific reported net sales of $5.44 billion, representing 7.5% year-over-year growth. Net income rose to $907 million from $797 million in the same period of 2025. However, key growth segments underperformed:

• Watchman: Sales of $507 million, up only 4.3% year over year. The unit had grown nearly 30% in 2025 to $1.96 billion. Mahoney noted a “dramatic” shift over the last six months, with declines in standalone Watchman procedures partially offset by growth in concomitant procedures. The company forecasts Watchman growth to be flat to low single digits for the full year, with the second half declining mid- to high-single digits. No improvement in standalone procedures is anticipated for the remainder of 2026.

• Electrophysiology: Sales of $916 million, up just over 9% year over year but showing minimal growth compared to the first quarter. Competitive pressure in PFA from Medtronic, Johnson & Johnson, and Abbott has eroded Boston Scientific’s market share. Mahoney stated, “We did undercall the competitive pressures in the U.S. in terms of share taking. We continue to be the PFA leader, but our share has come down.” PFA now represents 80%–85% of U.S. ablation procedures, limiting the ability to offset share loss through market expansion.

Mahoney emphasized that the remaining three-quarters of Boston Scientific’s business (excluding electrophysiology and Watchman) continues to grow at about 6% year over year.

Why It Could Matter

Boston Scientific’s struggles reflect broader dynamics in two of the most closely watched medtech markets. The Watchman franchise, once a high-growth driver, faces maturity and shifting procedure mix. LAAC remains a valuable therapy for stroke prevention in patients unsuitable for oral anticoagulation, but the rate of new implantations appears to be slowing following years of rapid adoption. The company’s reluctance to forecast Watchman growth in 2027 suggests a prolonged period of adjustment.

In electrophysiology, the PFA market is transitioning from hypergrowth (2024–2025) to a more competitive, saturated phase. As the dominant ablation modality becomes commoditized, differentiation will rely on workflow integration, mapping accuracy, and durable outcomes. Boston Scientific’s ability to defend its early leadership position against large rivals will be tested.

The company’s restructuring program, with expected pre-tax charges of $700–$800 million and run-rate savings of approximately $500 million, signals a strategic pivot to streamline operations and reinvest in areas of stronger growth.

Important Limitations

This report is based on company-provided financial data and management commentary from an earnings call. The guidance cuts reflect internal forecasts and may not fully capture market dynamics. Independent verification of procedure volume, competitive share, and regulatory impacts (e.g., reimbursement changes) is not available from this source. Projections for 2027 are qualitative and subject to change. The restructuring details and savings estimates may be adjusted as plans are implemented.

Regulatory and Implementation Context

Watchman and PFA systems have received FDA clearance and CE marking for their respective indications. The Watchman device (Watchman FLX) is approved for stroke prevention in patients with non-valvular atrial fibrillation. Farapulse PFA system received FDA approval in 2024. The current guidance changes do not reflect any new regulatory actions; they are driven by market and competitive forces. Reimbursement status for LAAC and AFib ablation remains stable in major markets, but any future changes could influence adoption rates.

Boston Scientific expects continued pressure in electrophysiology and Watchman through 2026 and into 2027, with no improvement in standalone Watchman procedures anticipated for the remainder of this year. The restructuring will likely result in workforce reductions and operational consolidation, with full run-rate savings expected only after the program concludes around 2029. The company’s ability to innovate in PFA, potentially with next-generation catheters or integrated mapping solutions, and to reinvigorate LAAC growth through new indications or physician education, will be critical. Investors and clinicians will watch for updates in upcoming quarters, including product launches and clinical trial results.